Limaca Medical Unveils Precision-GI™ Device Revolutionizing Biopsy Procedures in the US

Introduction Limaca Medical Ltd. has made a significant entrance into the United States healthcare market with the launch of its innovative Precision-GI™ device. This endoscopic automated motorized EUS biopsy tool is designed to enhance the biopsy procedures for patients suffering from suspected gastrointestinal cancers. With its recent FDA clearance and continued support through clinical trials and reimbursement pathways, Limaca is poised to redefine cancer diagnostics. ## The Precision-GI™ Device The Precision-GI™ device incorporates advanced technology, notably its motorized, automated, rotating cutting mechanism. This feature allows for improved tissue acquisition, promoting higher quality samples for histopathological and molecular analysis. The system is particularly effective in extracting samples from the GI tract, pancreas, liver, and surrounding organs, ensuring better diagnostic accuracy. As reported by medical professionals like Dr. Carlos Robles-Medranda, the device provides remarkably consistent biopsy samples, significantly reducing blood content in the samples and achieving efficiency during procedures. ## Clinical Success A pivotal clinical trial conducted at the IECED Medical Center demonstrated the device's capabilities. Under the lead of Dr. Robles-Medranda, the study involved 40 patients, primarily focusing on biopsies of solid pancreatic masses and liver lesions. The results were overwhelmingly positive, showcasing the Precision-GI™'s ability to deliver high-quality tissue samples. Dr. Robles-Medranda praised the device for its ease of use, noting, "The procedure with Precision GI is super easy for the physician and the results after just one pass are phenomenal." This validation marks a vital step forward in gastrointestinal cancer diagnostics. ## Strategic Market Entry With robust manufacturing capabilities in place, Limaca has effectively targeted its initial market within the New York/New Jersey Metro area. The company recently appointed Michael Davis as Sales Director, who brings extensive experience from multinational medical device firms. This strategic move indicates Limaca's commitment to expanding its footprint in the US market. Preliminary cases have already been completed at three medical centers in New York, with further partnerships on the horizon. The transitional pass-through (TPT) designation from CMS provides crucial financial support to hospitals adopting Precision-GI™, thereby streamlining its integration into healthcare systems. ## Expert Integration Medical experts, such as Dr. Rosario Ligresti, also endorse the Precision-GI™ device, highlighting its potential to drive forward precise biopsy results. Dr. Ligresti's experience in successfully conducting over twenty procedures exemplifies the cutting-edge capabilities of Limaca's technology. He noted, "I am excited to partner with Limaca to help bring an amazing automated, 20 gauge EUS biopsy needle to the USA." ## Future Growth and Outlook Looking to the future, Limaca's CEO Assaf Klein expressed confidence in their position within the industry, stating, "Our progress over the past year has positioned Limaca as a leader in innovative endoscopic biopsy solutions." With promising advancements and a committed operational team, Limaca Medical aspires to deliver superior diagnostic solutions, ultimately ensuring better outcomes for patients and enhanced procedural experiences for healthcare providers. ## About Limaca Medical Headquartered in Israel, Limaca Medical Ltd. is dedicated to enhancing endoscopic biopsy results for patients facing potentially life-threatening cancer diagnoses. Backed by reputable funding bodies, including the Israeli Innovation Authority and other investors, the company is laying the groundwork for its future in medical innovation. Limaca Medical's dedication to excellence and effectiveness places them at the forefront of advancing healthcare technology.